Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Feature|Articles|March 3, 2026
2026 ACS Report Shows CRC Rising in Younger Adults Despite Overall Decline
Author(s)Brooke McCormick
Fact checked by: Julia Bonavitacola
These new data highlight CRC screening gaps, as well as disparities in incidence and survival.
Advertisement
Advertisement
Although overall
Related to this article
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
Advertisement
Advertisement